每经AI快讯，10月14日，今日可申购科创板新股禾元生物，禾元生物发行总数约8945万股，申购代码 为：787765，申购价格：29.06元，单一账户申购上限1.4万股。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company He Yuan Bio is set to launch an IPO on the Sci-Tech Innovation Board with a total market value of 7.789 billion yuan and an issue price of 29.06 yuan per share [2]. Group 1: Company Overview - He Yuan Bio utilizes a rice endosperm cell bioreactor technology platform (OryzPur) for efficient recombinant protein production [2]. - The company is a pioneer in China in using rice endosperm cell bioreactors for drug production [2]. - The main business composition includes 80.64% from recombinant human albumin (pharmaceutical excipients, research reagents) and 19.36% from other sources [2]. Group 2: Financial Performance - The company reported a net profit of 25.22 million yuan in the last three years, with a projected increase of 3.92% in 2024 [3]. - Revenue for 2023 reached 24.26 million yuan, marking an 81.08% increase compared to the previous year [3]. - The net profit for 2022 was 13.40 million yuan, reflecting a decrease of 47.49% from 2021 [3]. Group 3: Fundraising Purpose - The funds raised will be directed towards the construction of a recombinant human albumin industrialization base and new drug research and development projects [3].

Core Insights - Yunding Xinyao announced the successful enrollment of the first patient in its global multicenter Phase I clinical trial for the universal off-the-shelf cancer therapeutic vaccine EVM14 at NEXT Oncology Virginia in the United States [1] Group 1: Product Overview - EVM14 is a universal off-the-shelf cancer therapeutic vaccine targeting five tumor-associated antigens (TAA) [1] - The vaccine is intended for the treatment of various squamous cell carcinomas, including non-small cell lung squamous carcinoma (sq-NSCLC) and head and neck squamous cell carcinoma (HNSCC) [1]

智通财经APP获悉，10月14日，禾元生物(688765.SH)开启申购，发行价格为29.06元/股，申购上限为1.4万股，属于上交所，国泰海通证券为其保荐机构。 招股书披露，禾元生物是一家创新型生物医药企业，拥有全球领先的植物生物反应器技术平台，建立了具有自主知识产权的水稻胚乳细胞生物反应器表达体 系，建立了完善的植物分子医药(Molecular Pharming)产业化体系，公司基于水稻胚乳细胞生物反应器的表达体系开发了多款药品、药用辅料及科研试剂等产 品。 根据上述沟通会议结果，公司拟进一步与美国FDA、中国CDE及欧洲药品管理局(EMA)沟通具体临床设计并达成一致后，开展一项纳入中国患者的全球多中 心III期临床研究，待研究完成后，同步向美国FDA及欧洲 EMA 申报药品上市，并向中国CDE申请 HY1001 的适应症拓展，预计获批后HY1001将实现在 中、美、欧上市销售，并取得血浆来源的人血清白蛋白全部现行适应症。 财务方面，于2022年度、2023年度、2024年度，公司实现营业收入分别约为1339.97万元、2426.41万元、2521.61万元，同期实现净利润分别约为-1.44亿 元、-1. ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688062 证券简称：迈威生物 公告编号：2025-060 迈威（上海）生物科技股份有限公司 自愿披露关于7MW3711在2025年 欧洲肿瘤内科学会（ESMO）以海报形式 报告数据及最新进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、迈威（上海）生物科技股份有限公司（以下简称"迈威生物"或"公司"）靶向B7-H3的抗体偶联新药 7MW3711将在2025年欧洲肿瘤内科学会（ESMO）大会中以海报形式报告在晚期实体瘤患者中的I/II期 临床研究数据及最新进展：截至2025年9月15日，在4.0mg/kg或以上剂量组的54例可肿评患者中，共有 19例患者达到部分缓解（PR）或完全缓解（CR）。在4.0mg/kg或以上剂量组的7例可肿评食管癌 （EC）患者中，ORR为42.9%，DCR为100.0%。在4.0mg/kg剂量组（每2周给药1次）的可肿评肺癌患者 中，10例小细胞肺癌（SCLC）和13例肺鳞癌（Sq-NSCLC）的客观缓解 ...

Core Insights - He Yuan Bio has developed an innovative technology called "rice blood production" over nearly 20 years, focusing on rice endosperm cell bioreactor technology, which has led to the establishment of efficient recombinant protein expression and purification platforms [2] - The company's core product, recombinant human albumin injection (from rice), was approved for market release in July this year, marking a significant shift from reliance on plasma extraction for such products [2] - He Yuan Bio has secured over 80 invention patents and built an intelligent production line capable of producing 10 tons of raw liquid and 1 million dosage forms annually, establishing a sales network across more than 30 provinces and cities in China [2] - The company is set to begin construction of a new industrial base project in September 2024, which will have an annual production capacity of 120 tons of raw liquid, enhancing its competitive edge in the recombinant human albumin market [2] Industry Context - He Yuan Bio is the first company to pass the review under the fifth set of standards of the Sci-Tech Innovation Board after its restart, highlighting the capital market's support for technological innovation and its adaptability to high-quality tech enterprises [3] - The successful listing of He Yuan Bio on the capital market represents a milestone in its development, indicating the company's entry into a new phase with unlimited potential [3] - The underwriting and sponsorship by Guotai Junan Securities emphasizes the commitment to providing professional services in the capital market, ensuring compliance with relevant regulations during the IPO process [4]

Core Viewpoint - Wuhan Heyuan Biotechnology Co., Ltd. successfully held an online investor communication meeting regarding its initial public offering (IPO) and listing on the Sci-Tech Innovation Board, emphasizing the importance of investor engagement and feedback for future growth [2][3] Company Overview - The company expressed gratitude to investors for their interest and questions during the IPO process, highlighting the role of various intermediaries and platforms in facilitating this communication [2] - The company aims to integrate constructive suggestions from investors into its management practices to enhance performance and build trust [2] Technology and Product Focus - Investors showed significant interest in the company's innovative "rice blood-making" technology and its commercialization progress, indicating a strong market potential [2] - The company is committed to advancing research and development (R&D) and industrialization processes to ensure sustainable growth [2] Corporate Governance and Market Communication - The company recognizes its responsibilities as a public entity and is dedicated to adhering to listing regulations, improving corporate governance, and maintaining transparent communication with the capital market [2] - The listing on the Sci-Tech Innovation Board is viewed as a critical milestone and the beginning of a new journey for the company [2] Future Outlook - The company looks forward to ongoing communication with investors and stakeholders, aiming to create value and share growth opportunities in the future [3]

Core Viewpoint - He Yuan Bio aims to provide green, safe, accessible, and sufficient biopharmaceutical products globally, addressing the challenge of relying on imported human serum albumin due to domestic plasma supply limitations [2][3] Group 1: Company Overview - He Yuan Bio has developed a leading plant bioreactor technology platform, achieving a breakthrough in human albumin expression levels of 20-30g/kg of brown rice [2] - The core product, OsrHSA, received approval from the National Medical Products Administration in July, marking the end of reliance on plasma extraction for human albumin and eliminating risks of human-derived pathogen transmission [2][3] Group 2: Production and Growth Strategy - The company has established a complete industrialization system covering pharmaceuticals, pharmaceutical excipients, and research reagents, completing the transition from technical breakthroughs to industrial implementation [3] - He Yuan Bio has built a cGMP intelligent production line with an annual capacity of 10 tons of OsrHSA raw solution and formulations, with a 120-ton raw solution production line under construction, set to enhance market competitiveness [3] Group 3: Future Outlook - The upcoming IPO is seen as a strategic leap in He Yuan Bio's development, leveraging the advantages of the rice endosperm cell expression platform to enhance operational management and project construction efficiency [3] - The company aims to create a world-class biopharmaceutical firm centered on recombinant protein drugs, continuously enhancing its core competitiveness and industry influence [3]

Group 1 - The core point of the news is that Junshi Biosciences has experienced a decline in stock price, dropping 1.77% to 38.91 CNY per share, with a total market capitalization of 39.949 billion CNY and a cumulative drop of 6.15% over the past three days [1] - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 90.67% of its revenue coming from drug sales [1] - The company is headquartered in Shanghai, with additional offices in Hong Kong, and was listed on July 15, 2020 [1] Group 2 - From the perspective of fund holdings, only one fund under Huatai-PineBridge has a significant position in Junshi Biosciences, with a reduction of 10.87 thousand shares in the second quarter, now holding 166.23 thousand shares, representing 4.89% of the fund's net value [2] - The fund, Huatai-PineBridge CSI Precision Medicine Index (LOF) A, has reported a floating loss of approximately 116.36 thousand CNY today and a total floating loss of 423.89 thousand CNY during the three-day decline [2] - The fund was established on January 21, 2016, with a current scale of 778 million CNY and has achieved a year-to-date return of 41.21% [2]

中美新一轮博弈的演绎及对市场将带来哪些影响？ 20251012 特朗普希望改变原来的贸易协议主要有两个原因。一方面，他认为给中国的条 件过于优厚，尤其是在 7 月份之后美国陆续与越南、欧盟等国家达成贸易协议 本轮贸易摩擦中，美国政治经济压力小于 4 月份，市场调整幅度有限， 资金动能转负但长线资金托举，科创板、半导体、电商等科技主线流入 明显。 中美博弈期间，科技（自主可控方向如国产软件、军工、半导体、有色 稀土、黄金）和金融股受益明显，新消费领域因基本面向上也将受到关 注。 摘要 中国稀土管制措施公开化，但未对美国企业产生实质影响，中美博弈中， 美国增加要价，中国寻求应对之策，但中国官方对特朗普关税威胁反应 滞后，显示冲击超出预期。 特朗普希望改变贸易协议，认为对华条件优厚，通过第三方加税、限制 生物制药和家具等间接施压，并试图在 APEC 前迫使中国在 TikTok、农 产品和稀土等方面让步。 中国对特朗普新要求采取谨慎回应，寻求对价，如收购美国科技企业或 降低分太离关系，并宣布系统相关产品需授权，以抗衡美国施压，但引 发美国加征关税。 中美博弈可能持续僵持，通过小动作互相施压，寻求谈判筹码，导致中 美关 ...